The Oncogenic Role of Human Microcephalin Gene Revealed by Pan-Cancer Analysis

Zerui Wang; Mian Li; Zhen Liu; Weiming Kang; Yazhou Cui; Jinxiang Han; Wenbin Du

doi:10.1101/2022.11.18.22282275

Abstract

The human gene microcephalin (MCPH1) plays a key role in DNA damage-induced cellular responses and chromosome condensation. Recent clinical studies proposed MCPH1 as a tumor suppressor gene in lung cancer, pancreatic cancer, and breast cancer, yet its roles remain poorly understood in other types of tumors. Pan-cancer analyses of MCPH1 are urgently required to help us understand the potential molecular functions of MCPH1 in other types of tumors. Here, we used several bioinformatic database and tools, including TCGA, GEO, ONCOMINE, and Human Protein Atlas to investigate the role of MCPH1 in 33 tumor types. We found that the expression of MCPH1 in tumor cases and normal cases were significantly different, and the higher expression of MCPH1 generally predicted poor overall survival for tumor patients, such as acute myeloid leukemia, liver hepatocellular carcinoma, and pancreatic adenocarcinoma. Meanwhile, lower expression of the MCPH1 gene was related to poor OS prognosis for KIRC and gastric cancer. Moreover, the expression level of MCPH1 was highly associated with the immune microenvironment. Our result provides some fresh light into the oncogenic roles of MCPH1 in various human cancers and revealed that MCPH1 may be a potential diagnostic and prognostic marker in LAML, PAAD, and gastric cancer.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

National Key Research and Development Program of China (2021YFC2301000 and 2021YFA0717000), National Natural Science Foundation of China (21822408, 41977196, and 91951103), and the Academic Promotion Programme of Shandong First Medical University (2019LJ001)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The raw data of this study are derived from the TCGA and GEO, which are publicly available databases.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes